The phase 2-phase 3 trial is being conducted in conjunction with the National Institute of Allergy and Infectious Diseases, the company said in a statement on Tuesday. The study is expected to enroll approximately 6,750 participants in the U.S. and Canada.
The Cambridge, Massachusetts-based company’s shares rose 5.2% to $151.14 at 10:12 a.m. in New York trading.
The two-part study will look at three dose levels in the youngest children and two ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.